A new article in BMJ Global Health presents the current situation of National Immunisation Programme (NIP) and identifies main challenges and opportunities for introducing vaccines in China. Many middle-income countries ineligible for support from the Global Alliance for Vaccines and Immunisation have relatively slow progress in introducing new critical vaccines, due largely to financial constraints. China has not introduced any vaccines into the NIP since 2008. Its funding for the NIP, relying solely on the government budget, has been decreasing as the number of targeted children has declined.
The main challenges identified are fluctuating and insufficient financing, restrictions on using health insurance funds for immunisation, high prices for non-NIP vaccines and the complicated and non-transparent decision-making mechanism to adjust NIP. Alongside these challenges, there are also opportunities for introducing vaccines, such as local pilots to provide free or subsidised new vaccines and reducing domestic vaccine prices. Feasible options to optimise NIP financing in China include increasing government funding, diversifying financing channels such as using health insurance funds, improving the vaccine procurement mechanism and optimising the new vaccine introduction decision-making process.
Thumbnail image credit: YIUCHEUNG / Shutterstock.com
Any organization or individual working in the field of immunization economics can submit findings, opportunities, calls to action, or other relevant work below to be shared with our community.